Table 1.
Demographic and Baseline Characteristics
| DOR/3TC/TDF | EFV/FTC/TDF | Total | |
|---|---|---|---|
| (N = 364) | (N = 364) | (N = 728) | |
| Age (years), Median (range) | 32.0 (18, 70) | 30.0 (18, 69) | 31.0 (18, 70) |
| Male, n (%) | 305 (84%) | 311 (85%) | 616 (85%) |
| Race, n (%) | |||
| White | 177 (49%) | 170 (47%) | 347 (48%) |
| Black or African American | 67 (18%) | 68 (19%) | 135 (19%) |
| Asian | 59 (16%) | 65 (18%) | 124 (17%) |
| Othera | 61 (17%) | 61 (17%) | 122 (17%) |
| Hispanic or Latino Ethnicity | 126 (35%) | 120 (33%) | 246 (34%) |
| Region, n (%) | |||
| Africa | 37 (10%) | 27 (7%) | 64 (9%) |
| Asia/Pacific | 59 (16%) | 62 (17%) | 121 (17%) |
| Europe | 88 (24%) | 94 (26%) | 182 (25%) |
| Latin America | 89 (24%) | 87 (24%) | 176 (24%) |
| North America | 91 (25%) | 94 (26%) | 185 (25%) |
| CD4+ T-Cell Count | |||
| Median (range), cells/mm3 | 414 (19, 1399) | 388 (19, 1452) | 397 (19, 1452) |
| ≤200 cells/mm3, n (%) | 44 (12%) | 46 (13%) | 90 (12%) |
| >200 cells/mm3, n (%) | 320 (88%) | 318 (87%) | 638 (88%) |
| Plasma HIV-1 RNA | |||
| Median (range), log10 copies/mL | 4.4 (2.4, 6.1) | 4.5 (2.6, 6.4) | 4.4 (2.4, 6.4) |
| ≤100000 copies/mL, n (%) | 291 (80%) | 282 (77%) | 573 (79%) |
| >100000 copies/mL, n (%) | 73 (20%) | 82 (23%) | 155 (21%) |
| History of AIDS, n (%) | 46 (13%) | 53 (15%) | 99 (14%) |
| Hepatitis B and/or C,b n (%) | 11 (3%) | 9 (2%) | 20 (3%) |
| HIV-1 Subtype B, n (%) | 232 (64%) | 253 (70%) | 485 (67%) |
Abbreviations: DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate at 300 mg; EFV/FTC/TDF, efavirenz at 600 mg, emtricitabine at 200 mg, and tenofovir disoproxil fumarate at 300 mg; HIV, human immunodeficiency virus; RNA, ribonucleic acid.
aOther race includes multiracial, American Indian, or Alaska Native.
bEvidence of hepatitis B surface antigen or hepatitis C virus RNA.